Faster Biopharma R&D: What Could Go Wrong?
Source: Bioprocess Online
Capital and human resources are prerequisite to R&D efficiency, and there’s never enough supply of either. In this segment of the Bioprocess Online Live event Bioprocess R&D: Beginning With The End In Mind, Cullinan Oncology President & CEO Nadim Ahmed and Amgen VP of Research Dr. Robert Stoffel discuss how they’re mitigating those risks with platforms and technology.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more